Biogen strikes deal with Isis to develop drugs for ALS, other diseases
This article was originally published in Scrip
Executive Summary
Biogen Idec is paying $100 million to Isis Pharmaceuticals in a collaborative effort to develop treatments for neurological diseases, such as ALS.